Radiologists

Discover how NeuroQuant can provide your referring physicians with critical information about neurodegeneration identifiable in standard 3D T1-weighted brain images.

NeuroQuant is a breakthrough medical device that is the first FDA cleared, CE marked, and Health Canada licensed software for fully-automatic labeling, visualization and volumetric quantification of brain structures important in the assessment of neurodegenerative conditions from ages 3 to 100. The procedure may be reimbursed by Medicare under CPT 76377 and occurs wholly within your existing PACS infrastructure. Volumes and atrophy reports are automatically generated for your review prior to incorporating into your report. So, you can make quantitative segmental volume reporting and assessment a routine part of your analysis, without the need for a separate 3D processing lab.

Gone are the days of ambiguous, unhelpful and potentially misleading statements, such as “mild involutional changes” and “age-appropriate atrophy.” NeuroQuant will help you provide objective data back to the referring physician. With precise, volumetric data at your fingertips, you can:

Enhance Reports

with information never before provided in the standard radiological read, which has traditionally focused on discrete lesions.

Provide Totality

in your assessment of brain images to your referring physicians to deservedly win their referrals.

Track Progression

of brain atrophy with longitudinal scans that trace volume loss quantitatively.

Boost Referrals

along with usage of MRI equipment, as NeuroQuant provides meaningful information beyond the simple ruling out of structural or lesion-based etiologies of patient complaint.

Offer Expertise

by providing hippocampal volumetry, the only Alzheimer’s biomarker that is consistently reimbursed by Medicare (Quantitative Segmental Volume Reporting and Assessment). NeuroQuant is also the first FDA cleared and CE marked product to provide brain structure volumes equivalent to expert manual segmentation.

Ask Yourself
“How often do I get referrals for cognitive impairment or seizure?” “How often do I provide meaningful information about the possible presence of neurodegeneration to my referring physicians?” Because of the huge prevalence of prodromal and frank Alzheimer’s disease, the answer is surely that this clinically relevant information was missed in many of the scans.

Gone are the days of ambiguous, unhelpful and potentially misleading statements, such as “mild involutional changes” and “age-appropriate atrophy.” NeuroQuant will help you provide objective data back to the referring physician.